Filtered By:
Specialty: Cardiology
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 1444 results found since Jan 2013.

Eliminating Medication Copayments for Low-income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial
Conclusions: In low-income adults at high cardiovascular risk, eliminating copayments (average $35 a month) did not improve clinical outcomes or reduce healthcare costs, despite a modest improvement in adherence to medications.PMID:36871215 | DOI:10.1161/CIRCULATIONAHA.123.064188
Source: Circulation - March 5, 2023 Category: Cardiology Authors: David J T Campbell Chad Mitchell Brenda R Hemmelgarn Marcello Tonelli Peter Faris Jianguo Zhang Ross T Tsuyuki Jane Fletcher Flora Au Scott Klarenbach Derek V Exner Braden J Manns Interdisciplinary Chronic Disease Collaboration Source Type: research

The effect of intensive statin therapy in non-symptomatic intracranial arteries: The STAMINA-MRI sub-study
CONCLUSION: Intensive statin therapy produced a favorable morphological change in cerebral arteries of not only the target arterial segment but also non-symptomatic arterial segments. The change in cerebral arterial luminal diameter was influenced by the baseline SBP and was dependent on the topographic distribution of the cerebral arteries.Clinical Trial Registration: ClinicalTrials.gov, identifier NCT02458755.PMID:37056360 | PMC:PMC10088516 | DOI:10.3389/fneur.2023.1069502
Source: Atherosclerosis - April 14, 2023 Category: Cardiology Authors: Jae Eun Sim Ha-Na Song Jong-Un Choi Ji-Eun Lee In Young Baek Hwan-Ho Cho Jong-Hoon Kim Jong-Won Chung Gyeong-Moon Kim Hyun-Jin Park Oh Young Bang Woo-Keun Seo Source Type: research

Statins Tied to Lower Stroke Risk in Atrial Fibrillation Statins Tied to Lower Stroke Risk in Atrial Fibrillation
Initiation of statins soon after diagnosis of AF is associated with lower risk of ischemic and hemorrhagic strokes; longer-term use is tied to further benefit, a new study shows.Medscape Medical News
Source: Medscape Cardiology Headlines - April 28, 2023 Category: Cardiology Tags: Cardiology News Source Type: news

Investigation of Combined Carotid Endarterectomy and Coronary Artery Bypass Graft Surgery Outcomes and Adverse Event Risk Factors in the Vascular Quality Initiative
CONCLUSIONS: Combined CEA and CABG provides excellent long-term mortality prevention in patients with co-existing severe coronary and carotid atherosclerosis. Simultaneous CEA and CABG provides equivalent stroke prevention and long-term survival to both a cohort of patients undergoing coronary revascularization within 5 years of CEA and patients undergoing isolated CEA or CABG in the literature. The two most impactful modifiable risk factors towards long-term stroke and mortality prevention for patients undergoing simultaneous CEA-CABG are patch placement at CEA site and adherence to statin medication therapy.PMID:37303074...
Source: Atherosclerosis - June 11, 2023 Category: Cardiology Authors: Ashley Penton Jonathan Lin Grant Kolde Matthew DeJong Matthew Blecha Source Type: research

Assessing statins use in a real-world primary care digital strategy: a cross-sectional analysis of a population-wide digital health approach
Lancet Reg Health Am. 2023 Jun 22;23:100534. doi: 10.1016/j.lana.2023.100534. eCollection 2023 Jul.ABSTRACTBACKGROUND: The digitization of the primary care system provides an opportunity to evaluate the current use of statins in secondary prevention populations (myocardial infarction or stroke).METHODS: We conducted a cross-sectional study (ClinicalTrials.gov, NCT05285085), analysing anonymised data routinely collected by community health workers (CHW) in Brazil between May 2016 and September 2021 to assess the proportion of self-reported statins use and associated factors.FINDINGS: From the 2,133,900 individuals on the da...
Source: Atherosclerosis - July 27, 2023 Category: Cardiology Authors: M Julia Machline-Carrion Alysson Nathan Girotto Josu é Nieri Pedro Marton Pereira Frederico Monfardini Francisco Forestiero Priscila Raupp Fabiana Roveda Karla Santo Ot ávio Berwanger Raul D Santos Source Type: research

DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE < sup > -/- < /sup > mice via suppressing inflammation, endothelial necroptosis and apoptosis
This study aims to explore whether NBP is able to improve endothelium-dependent vasodilation in atherosclerosis and the underlying mechanisms. Male ApoE-/- mice were fed with a high-fat diet (HFD) for 9-16 weeks to establish a model of atherosclerosis. NBP were given to the mice after eating HFD for 6 weeks and atorvastatin served as a positive control. The endothelium-dependent vasodilation, the blood flow velocity, the atherosclerotic lesion area, the serum levels of lipids, inflammatory cytokines and necroptosis-relevant proteins (RIPK1, RIPK3 and MLKL), and the endothelial necroptosis and apoptosis within the aorta wer...
Source: Atherosclerosis - August 3, 2023 Category: Cardiology Authors: Li-Qun Lu Nian-Sheng Li Ming-Rui Li Jiao-Yang Peng Li-Jing Tang Xiu-Ju Luo Jun Peng Source Type: research

Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events
CONCLUSIONS AND RELEVANCE: A protein risk score was significantly associated with ASCVD events in primary and secondary event populations. When added to clinical risk factors, the protein risk score and polygenic risk score both provided statistically significant but modest improvement in discrimination.PMID:37606673 | DOI:10.1001/jama.2023.13258
Source: Atherosclerosis - August 22, 2023 Category: Cardiology Authors: Hannes Helgason Thjodbjorg Eiriksdottir Magnus O Ulfarsson Abhishek Choudhary Sigrun H Lund Erna V Ivarsdottir Grimur Hjorleifsson Eldjarn Gudmundur Einarsson Egil Ferkingstad Kristjan H S Moore Narimon Honarpour Thomas Liu Huei Wang Thomas Hucko Marc S S Source Type: research

Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: A post hoc analysis of the MEGA Study.
CONCLUSION: Pravastatin therapy provided significant risk reductions for CHD and CVD in patients with phenotype IIa dyslipidemia, but not in those with phenotype IIb dyslipidemia. PMID: 23265677 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - December 19, 2012 Category: Cardiology Authors: Nishiwaki M, Ikewaki K, Ayaori M, Mizuno K, Ohashi Y, Ohsuzu F, Ishikawa T, Nakamura H, for the MEGA Study Group Tags: J Cardiol Source Type: research

Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy Effect of Baseline Risk Factors for Diabetes
ConclusionsCompared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of NOD in patients with 0 to 1 NOD risk factors but did, by 24%, among patients with 2 to 4 NOD risk factors. The number of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 7, 2013 Category: Cardiology Source Type: research

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
The objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascular events in patients with clinically stable coronary disease.BackgroundThe presence of activated neutrophils in culprit atherosclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition of neutrophil function with colchicine may reduce the risk of plaque instability and thereby improve clinical outcomes in patients with stable coronary disease.MethodsIn a clinical trial with a prospective, randomized, observer-blinded endpoint design, 532 patients with stable coronary diseas...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 21, 2013 Category: Cardiology Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention A Systematic Review and Meta-Regression
ConclusionsThe consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 21, 2013 Category: Cardiology Source Type: research

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
The objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascular events in patients with clinically stable coronary disease. Background: The presence of activated neutrophils in culprit atherosclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition of neutrophil function with colchicine may reduce the risk of plaque instability and thereby improve clinical outcomes in patients with stable coronary disease. Methods: In a clinical trial with a prospective, randomized, observer-blinded endpoint design, 532 patients with stable coron...
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Stefan M. Nidorf, John W. Eikelboom, Charley A. Budgeon, Peter L. Thompson Tags: Clinical Trial Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention: A Systematic Review and Meta-Regression
Conclusions: The consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Paul M. Lavigne, Richard H. Karas Tags: Cardiometabolic Risk Source Type: research